This week in charts: Brain drugs are back on venture capitalists’ minds

Neuroscience startups raised $1.9B in 2025, with $664M raised by mid-November 2026. Oyster Therapeutics secured $60M for Alzheimer's research. Cell therapy stocks saw mixed reactions to new data, with Cabaletta Bio up 5% and others like Nkarta down over 20%.

Original reporting
Published Nov 13, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 2:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This week in charts: Brain drugs are back on venture capitalists’ minds — source image
Decision brief

The 30-second read

$NKTXBearishLow
01

Why it matters

The mixed signals—new funding for CNS startups versus sharp declines in cell‑therapy stocks—suggest a bifurcated market sentiment within biotech.

02

Market read

Provides traders with fresh data on funding trends and immediate price reactions for several biotech stocks.

03

What to watch

The article does not discuss pipeline depth, partnership deals, or upcoming regulatory milestones that could mitigate short‑term weakness.

Relevance 4/10Novelty 4/10Timing: this week

Background

The piece recaps recent venture capital funding in neuroscience and summarizes investor reactions to cell‑therapy data presented at a major rheumatology conference.

Company-level read

Ticker impact

$NKTXBearishMedium confidence
Context

Nkarta shares fell more than 20% between Nov. 6 and Nov. 12 after recent cell‑therapy data disappointed investors.

Expected impact

likely continued pressure unless new data reverses sentiment

Evidence & confidence

The article reports a >20% drop tied to recent research updates.

$ALLOBearishMedium confidence
Context

Allogene Therapeutics shares dropped over 20% in the same period after cell‑therapy updates.

Expected impact

downward pressure may persist in the short term

Evidence & confidence

Price decline is highlighted as a reaction to recent trial information.

$FATEBearishMedium confidence
Context

Fate Therapeutics shares fell more than 20% following recent cell‑therapy conference results.

Expected impact

likely further downside absent positive news

Evidence & confidence

The article links a >20% drop to the latest conference data.

$CRSPBearishMedium confidence
Context

CRISPR Therapeutics declined nearly 15% after the same conference updates.

Expected impact

potential continued weakness in the near term

Evidence & confidence

The article notes a 15% decline tied to the conference outcomes.

Market effects

Highlights renewed VC interest in neuroscience and cautious investor reaction to cell‑therapy data, suggesting sector volatility.

Primarily U.S. biotech equities; limited broader market effect.

Signals potential shift in funding trends for CNS drug startups worldwide.

Counterpoint

Despite recent price drops, some investors may view the pull‑back as a buying opportunity if long‑term data improves.

Key entities

  • Oyster Therapeutics

    London‑based CNS biotech that raised $60 million in a Series A round.

  • Cabaletta Bio

    Cell‑therapy developer reporting early trial data.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$NKTXHighAI 8/10

Nkarta reports safety data for autoimmune cell therapy NKX019

Nkarta Inc. (NKTX) presented safety data for NKX019, its CD19-directed CAR NK cell therapy, in a clinical trial for autoimmune diseases. The data, from 40 patients, showed no serious adverse events. Treatment-emergent adverse events occurred in 85% of patients, with 35% experiencing grade 3 or higher events, primarily hematologic. NKX019 is manufactured from donor-derived NK cells.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.